What is Juventas?
Juventas Cell Therapy Ltd. is a China-based biopharmaceutical firm established in 2018. The company is dedicated to the clinical translation and commercialization of novel immune cell therapies. With operations centered in Beijing and a GMP facility located in Tianjin City, Juventas focuses on developing advanced treatments for critical medical conditions. Its strategic focus on immune cell therapy positions it within a rapidly evolving sector of biotechnology, aiming to address unmet medical needs through innovative therapeutic solutions.
How much funding has Juventas raised?
Juventas has raised a total of $75.4M across 2 funding rounds:
Series A
$15.4M
Series C
$60M
Series A (2019): $15.4M with participation from CASI Pharmaceuticals
Series C (2021): $60M led by Jiadao Private Capital, Delian Capital, Oceanpine Capital, CICC Capital, and Redhill Capital
Key Investors in Juventas
Jiadao Private Capital
Jiadao Private Capital is an investor participating in the funding round, likely focusing on strategic capital allocation within the biopharmaceutical sector.
Delian Capital
Delian Capital is an investor participating in the funding round, potentially specializing in growth-stage companies within the healthcare industry.
CASI Pharmaceuticals
CASI Pharmaceuticals is a global biopharmaceutical company focused on discovering, developing, and commercializing innovative therapies for cancer, autoimmune diseases, and organ transplant rejection. The company advances novel biologics, monoclonal antibodies, and oncology treatments to address unmet medical needs worldwide.
What's next for Juventas?
The substantial enterprise-level funding and recent strategic investment signal a pivotal phase for Juventas. This capital infusion is expected to accelerate the company's clinical development pipeline, enhance its manufacturing capabilities, and support its commercialization efforts. As Juventas advances its innovative immune cell therapies, the company is poised to expand its market presence and solidify its position as a key player in China's burgeoning biopharmaceutical industry. Future growth will likely involve further strategic partnerships and continued investment in research and development to maintain its competitive edge.
See full Juventas company page
